Patents Examined by Charanjit S. Aulakh
  • Patent number: 7915414
    Abstract: The present invention discloses organometallic complexes with transition metal elements and their application in fabrication of a variety of light-emitting devices. The mentioned organometallic complexes can serve as emitting material or dopant for blue phosphorescent organic light-emitting devices with excellent performance. The mentioned organometallic complexes have a general formula as the following: Wherein M represents a transition metal element, and Q1 and Q2 respectively represent an atomic group forming a nitrogen-containing heterocyclic ring as a five member ring, a six member ring, or a seven member ring.
    Type: Grant
    Filed: November 1, 2007
    Date of Patent: March 29, 2011
    Inventors: Yun Chi, Cheng-Han Yang, Pi-Tai Chou, Chung-Chih Wu, Chih-Hao Chang
  • Patent number: 7915264
    Abstract: The invention provides compounds of formula (I) wherein R1, R2, R3, R4, and R5 are as defined in the description, and the preparation thereof. The compounds of formula (I) are useful as pharmaceuticals.
    Type: Grant
    Filed: March 25, 2002
    Date of Patent: March 29, 2011
    Assignee: Novartis AG
    Inventors: Andrew James Culshaw, Peter Gull, Allan Hallett, Hong-Yong Kim, Max Peter Seiler, Kaspar Zimmermann, Yugang Liu, Mahavir Prashad
  • Patent number: 7915276
    Abstract: The present invention relates to a berberrubine derivative having superior antifungal activity, more particularly to a berberrubine derivative having activity against chitin synthase, which participates in the synthesis of chitin and is essential in the growth of fungi, and having a potent antifungal activity against human pathogenic fungi.
    Type: Grant
    Filed: November 6, 2006
    Date of Patent: March 29, 2011
    Assignee: Korea Research Institute of Bioscience and Biotechnology
    Inventors: Sung Uk Kim, Ki Duk Park, Jae Sun Moon, Tae Hoon Kang, Young Kook Kim
  • Patent number: 7910607
    Abstract: Nitroxide free radicals attached to antineoplastic agents can synergize their potencies to cancer cells. This invention relates to any antineoplastic agents and their derivatives chemically attached with nitroxide free radicals, such as TEMPO and its radical derivatives. This invention also relates to precursors of such compounds, as well as the products formed from the adducts after administration.
    Type: Grant
    Filed: March 12, 2007
    Date of Patent: March 22, 2011
    Assignee: The Trustees of California State University
    Inventors: Yong Ba, Errol V. Mathias
  • Patent number: 7910736
    Abstract: A method for producing an organic field-effect transistor, comprising the steps of: a) providing a substrate comprising a gate structure, a source electrode and a drain electrode located on the substrate, and b) applying an n-type organic semiconducting compound to the area of the substrate where the gate structure, the source electrode and the drain electrode are located, wherein the n-type organic semiconducting compound is selected from the group consisting of compounds of the formula I wherein R1, R2, R3and R4are independently hydrogen, chlorine or bromine, with the proviso that at least one of these radicals is not hydrogen, Y1 is O or NRa, wherein Ra is hydrogen or an organyl residue, Y2 is O or NRb, wherein Rb is hydrogen or an organyl residue, Z1, Z2, Z3 and Z4 are O, where, in the case that Y1 is NRa, one of the residues Z1 and Z2 may be a NRc group, where Ra and Rc together are a bridging group having 2 to 5 atoms between the terminal bonds, where, in the case that Y2 is NRb, one of the
    Type: Grant
    Filed: May 4, 2007
    Date of Patent: March 22, 2011
    Assignees: BASF Aktiengesellschaft, The Board of Trustees of the Lenand Stanford Junior University
    Inventors: Martin Koenemann, Peter Erk, Zhenan Bao, Mang-Mang Ling
  • Patent number: 7910737
    Abstract: The invention discloses the preparation method of 7-ethyl-10-hydroxycamptothecin from 4-ethyl-7,8-dihydro-4-hydroxy-1H-pyrano[3,4-f]indolizine-3,6,10(4H)-trione and 1-(2-amino-5-hydroxyphenyl)-propan-1-one using higher reaction temperature and faster heating to that temperature.
    Type: Grant
    Filed: February 6, 2006
    Date of Patent: March 22, 2011
    Assignee: Fermion Oy
    Inventor: Ilpo Laitinen
  • Patent number: 7906531
    Abstract: Muscarinic Acetylcholine receptor antagonists and methods of using them are provided.
    Type: Grant
    Filed: July 16, 2009
    Date of Patent: March 15, 2011
    Assignee: Glaxo Group Limited
    Inventors: Zehong Wan, Hongxing Yan, Michael R. Palovich, Dramane I. Laine
  • Patent number: 7902363
    Abstract: Diimide-based semiconductor materials are provided with processes for preparing the same. Composites and electronic devices including the diimide-based semiconductor materials also are provided.
    Type: Grant
    Filed: November 19, 2007
    Date of Patent: March 8, 2011
    Assignee: Polyera Corporation
    Inventors: Antonio Facchetti, Tobin J. Marks, He Yan
  • Patent number: 7902362
    Abstract: The invention is directed to a compound having the general formula (1): wherein each of La and Lb is an independently selected from a linking moiety comprising 0 to 10 main chain atoms, optionally substituted; each of Za and Zb is an independently selected complexing moiety comprising at least one nitrogen atom; either both or one of Za and/or Zb is coordinatively bonded to a respective transition metal complex Ma Va and Mb Vb through said nitrogen atom, wherein each of Ma and Mb is an independently selected transition metal, and each of Va and Vb is an independently selected valence group.
    Type: Grant
    Filed: December 22, 2008
    Date of Patent: March 8, 2011
    Assignee: Agency for Science, Technology & Research
    Inventors: Zhiqiang Gao, Fang Xie
  • Patent number: 7897610
    Abstract: The invention relates to the use of benzo[c]quinolizinium derivatives for treating diseases that are linked to smooth muscle cell constriction, such as hypertension and asthma.
    Type: Grant
    Filed: June 5, 2003
    Date of Patent: March 1, 2011
    Assignees: Centre National de la Recherche Scientifique, Universite de Poitiers
    Inventors: Frédéric Becq, Renaud Robert, Laurence Pignoux, Christian Rogier, Yvette Mettey, Jean Michel Vierfond, Michel Joffre, Cécile Marivingt-Mounir
  • Patent number: 7897617
    Abstract: The invention provides 3-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2] octane in salt form, pharmaceutical compositions comprising it, and methods of using it for treatment of respiratory disorders, in association with steroids.
    Type: Grant
    Filed: May 26, 2010
    Date of Patent: March 1, 2011
    Assignee: Almirall Prodesfarma S.A.
    Inventors: Maria Dolors Fernandez Forner, Maria Prat Quiñones, Maria Antonia Buil Albero
  • Patent number: 7893265
    Abstract: The present teachings provide compounds of formulae I and II: where Q, Ra, R1, W, and n are as defined herein. The present teachings also provide methods of preparing compounds of formulae I and II, including methods of preparing compounds of formula II from compounds of formula I. The compounds disclosed herein can be used to prepare semiconductor materials and related composites and electronic devices.
    Type: Grant
    Filed: January 7, 2008
    Date of Patent: February 22, 2011
    Assignee: Polyera Corporation
    Inventors: Antonio Facchetti, Tobin J. Marks, He Yan
  • Patent number: 7888512
    Abstract: Methods of synthesizing nicotine analogs and derivatives are described. In some embodiments the methods utilize an alkyl or aryl silyl-substituted nicotine analog intermediate. Intermediates useful for the synthesis of nicotine and nicotine analogs are also described.
    Type: Grant
    Filed: May 27, 2009
    Date of Patent: February 15, 2011
    Assignee: North Carolina State University
    Inventors: Daniel L. Comins, Emilie Despagnet Smith
  • Patent number: 7879886
    Abstract: Composition, article of manufacture for and method of treating malaria in a human having an infestation of Plasmodium protozoans are described. The method comprises administering a therapeutically-effective amount of a compound of formula (I) or (IV), i.e. sufficient quantity to reduce the population of Plasmodium. The composition of the invention is a compound of formula (I) or (IV) with a pharmaceutical excipient. The article of manufacture is the composition in combination with labeling for treating malaria. The substituents are detailed in the specification.
    Type: Grant
    Filed: October 17, 2006
    Date of Patent: February 1, 2011
    Assignee: University of Florida Research Foundation, Inc.
    Inventor: Raymond J. Bergeron, Jr.
  • Patent number: 7875718
    Abstract: This invention relates to intermediates useful in the preparation of opiate alkaloids, particularly morphinane compounds. The invention also relates to processes for preparing such intermediates and to processes which utilise such intermediates in the synthesis of morphinane compounds.
    Type: Grant
    Filed: March 19, 2007
    Date of Patent: January 25, 2011
    Assignees: Johnson Matthey Public Limited Company, GlaxoSmithKline Australia Pty. Ltd.
    Inventors: Craig Smith, Stuart Purcell, Lucy Waddell, Nicholas Hayes, Jarrod Ritchie, Scott Brian Halliday, Melville Mitchell, George Scott Wilson
  • Patent number: 7875628
    Abstract: The present invention provides compositions and methods for modulating smoothened-dependent pathway activation. The present invention provides analogs of cyclopamine that can be used to counteract the phenotypic effects of unwanted activation of a hedgehog pathway, such as resulting from hedgehog gain-of-function, Ptc loss-of-function or smoothened gain-of-function mutations. The compounds of the present invention are particularly useful in treating cancers.
    Type: Grant
    Filed: July 10, 2008
    Date of Patent: January 25, 2011
    Assignee: Infinity Discovery, Inc.
    Inventors: Julian Adams, Alfredo C. Castro, Michael A. Foley, Somarajannair Janardanannair, Marta Nevalainen, James R. Porter, Martin R. Tremblay
  • Patent number: 7875623
    Abstract: The present invention relates to processes for removal of Michael acceptors from certain compositions wherein the composition is treated with a thiol-containing compound under conditions sufficient to remove Michael acceptors and the resulting thiol-Michael adducts. Certain embodiments of the present invention enable quantification and/or removal of Michael acceptors and/or Michael acceptor precursors.
    Type: Grant
    Filed: November 22, 2006
    Date of Patent: January 25, 2011
    Assignee: Controlled Chemicals, Inc.
    Inventors: Jules A. Shafer, Vladislav V. Telyatnikov, Hao Wang
  • Patent number: 7875613
    Abstract: The present invention concerns new compounds of formula (I), their process of preparation and their therapeutic use wherein R3, R4, R5, R6, Y, Het1, T, U, V, W, X, Ru, Rv and Rw are as defined in claim 1.
    Type: Grant
    Filed: October 30, 2006
    Date of Patent: January 25, 2011
    Assignee: Hybrigenics SA
    Inventors: Philippe Guedat, Xavier Jacq, Frédéric Colland, Laurent Daviet, Etienne Formstecher, Jean-Christophe Rain, Matteo Colombo
  • Patent number: 7868170
    Abstract: The present invention relates to a platinum complex as the following formula (I): wherein X, n, R1, R2, R3,R4, R5, X1, X2, L1, and L2 are defined the same as the specification. The present invention also further provides an organic light-emitting device using the same. The complexes of the present invention exhibit enhanced emission quantum yields, and short phosphorescence radiative lifetimes in the range of several microseconds so as to be applied in high efficiency OLEDs.
    Type: Grant
    Filed: December 28, 2007
    Date of Patent: January 11, 2011
    Inventors: Yun Chi, Pi-Tai Chou, Sheng-Yuan Chang
  • Patent number: 7863447
    Abstract: A compound of the formula I or I?, where the radicals R1 are each, independently of one another, a hydrogen atom or C1-C4-alkyl and R?1 is C1-C4-alkyl; X1 and X2 are each, independently of one another, a sec-phosphino group; R2 is (1) hydrogen, (2) R01R02R03Si—, (3) C1-C18-acyl substituted with halogen, hydroxyl, C1-C8-alkoxy or R04R05N—, or (4) R06—X01—C(O)—; R01, R02 and R03 are each, independently of one another, C1-C12-alkyl, unsubstituted or C1-C4-alkyl- or C1-C4-alkoxy-substituted C6-C10-aryl or C7-C12-aralkyl; R04 and R05 are each, independently of one another, hydrogen, C1-C12-alkyl, C3-C8-cycloalkyl, C6-C10-aryl or C7-C12-aralkyl, or R04 and R05 together are trimethylene, tetramethylene, pentamethylene or 3-oxapentylene; R06 is C1-C18-alkyl, unsubstituted or C1-C4-alkyl- or C1-C4-alkoxy-substituted C3-C8-cycloalkyl, C6-C10-aryl or C7-C12-aralkyl; X01 is —O— or —NH—; T is C-bonded C3-C20-heteroarylene; v is 0 or an integer from 1 to 4; X1 in the heteroring of the heteroarylene is bound in the orth
    Type: Grant
    Filed: April 19, 2006
    Date of Patent: January 4, 2011
    Assignee: Umicore AG & Co., KG
    Inventors: Martin Kesselgruber, Marc Thommen, Matthias Lotz